Home » Stocks » Synlogic

Synlogic, Inc. (SYBX)

Stock Price: $2.00 USD -0.03 (-1.48%)
Updated Oct 22, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 68.33M
Revenue (ttm) 2.08M
Net Income (ttm) -57.45M
Shares Out 34.17M
EPS (ttm) -1.67
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 22, 2020
Last Price $2.00
Previous Close $2.03
Change ($) -0.03
Change (%) -1.48%
Day's Open 2.03
Day's Range 1.99 - 2.13
Day's Volume 375,596
52-Week Range 1.35 - 3.46

More Stats

Market Cap 68.33M
Enterprise Value n/a
Earnings Date (est) Nov 17, 2020
Ex-Dividend Date n/a
Shares Outstanding 34.17M
Float 20.13M
EPS (basic) -1.66
EPS (diluted) -1.67
FCF / Share -1.26
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 274,725
Short Ratio 1.82
Short % of Float 1.36%
Beta 1.94
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 32.84
PB Ratio 0.53
Revenue 2.08M
Operating Income -59.95M
Net Income -57.45M
Free Cash Flow -44.11M
Net Cash 86.22M
Net Cash / Share 2.52
Gross Margin -703.56%
Operating Margin -2,880.92%
Profit Margin -2,760.50%
FCF Margin -2,119.51%
ROA -20.02%
ROE -36.77%
ROIC -33.80%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (8)

Buy 6
Overweight 0
Hold 1
Underweight 0
Sell 1

Analyst Consensus: Buy

Price Target

$7.57*
(278.50% upside)
Low
2.00
Current: $2.00
High
13.00
Target: 7.57
*Average 12-month price target from 7 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year20192018201720162015201420132012
Revenue2.222.522.440.44----
Revenue Growth-11.75%3.11%450.45%-----
Gross Profit2.222.522.440.44----
Operating Income-54.41-51.23-40.82-20.96-25.03-13.91-6.78-4.30
Net Income-51.37-48.44-40.38-20.95-24.98-15.83-6.44-3.66
Shares Outstanding30.2823.886.722.980.720.01--
Earnings Per Share-1.70-2.03-6.00--40.95-2,036.96-30,859.93-2,614.79
Operating Cash Flow-75.47-42.47-31.06-20.41-21.14-13.97-6.50-4.52
Capital Expenditures-1.25-5.65-2.57-1.83-0.25-0.10-0.01-
Free Cash Flow-76.72-48.12-33.62-22.24-21.39-14.07-6.50-4.52
Cash & Equivalents12112488.1214.6489.719.329.32-
Total Debt25.010.480.890.38----
Net Cash / Debt95.6512387.2314.2689.719.329.32-
Assets18914099.7020.0490.929.839.83-
Liabilities31.6716.2414.6611.545.902.502.50-
Book Value15712485.048.5085.02-47.95-47.95-
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Synlogic, Inc.
Country United States
Employees 76
CEO Aoife M. Brennan

Stock Information

Ticker Symbol SYBX
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: SYBX

Description

Synlogic, a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its therapeutic programs include SYNB1618, an oral therapy that is in Phase I/IIa clinical trial to treat phenylketonuria. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine that is in Phase I clinical trial to treat solid tumors and lymphoma. It has a collaboration agreement with Ginkgo Bioworks for the development of synthetic biotic medicines. Synlogic, Inc. is headquartered in Cambridge, Massachusetts.